SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

PTC Therapeutics Raises Full-Year 2026 Revenue Guidance

PTC Therapeutics raised its 2026 total revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million, from a previous $850 million-$950 million range.

PTCT
SquawkNews Desk

Related stories

Viatris Commences Tender Offer to Acquire Pacira BioSciences M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC BofA Downgrades Intel to Neutral, Cuts Price Target to $100 BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100. M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8 M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC European session market picture: S&P 500 -1.1%, Nasdaq 100 -2.59%; EUR/USD +0.1%, WTI +1.86%, LLOY leads volume European session market picture. US index futures: S and P futures is down 1.1 percent, Nasdaq futures is down 2.59 percent, Dow futures is down 0.1 percent and Russell futures is M impact | EQUITY | Oct 30, 2026, 12:30 PM UTC Chevron Reports Q3 2026 Revenue of $67.8 Billion Chevron reported Q3 2026 revenue of $67.8 billion, up 36.3% year on year, and non-GAAP profit of $5.28 per share, 8.5% above analysts’ consensus estimates. H impact | EQUITY | Oct 30, 2026, 12:27 PM UTC Alphabet Shares Fall More Than 12% as Investors Weigh AI Spending Alphabet reported diluted earnings of $2.12 per share and quarterly revenue of $127.58 billion. Investors focused on rising infrastructure spending and negative free cash flow desp M impact | EQUITY | Oct 30, 2026, 12:26 PM UTC